The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study
Maurizio Muscaritoli(Policlinico Umberto I), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Silvia Quadrini(Policlinico Umberto I), Bruno Chiurazzi(Ospedale Antonio Cardarelli), Antonia Strippoli(Agostino Gemelli University Polyclinic), Filomena Narducci(Santissima Trinità), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), A. Lucenti(Azienda Usl 8 Arezzo), Giuseppe Tonini(Campus Bio Medico University Hospital), Teresa Grassani(Campus Bio Medico University Hospital), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Alessandra Modena(Ospedale Sacro Cuore Don Calabria), Fabrizio Nicolis(Ospedale Sacro Cuore Don Calabria), Luigi Cavanna(University of Pavia), Roberto Magarotto(Ospedale Sacro Cuore Don Calabria), Marcella Occelli, Camilla Di Nunzio(Guglielmo da Saliceto Hospital), Chiara Citterio(Guglielmo da Saliceto Hospital), Giuseppe Altavilla(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Matteo Valerio(Ospedale Sacro Cuore Don Calabria)
Cited by 27
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
ESPEN guidelines on nutrition in cancer patients
|Clinical Nutrition|2016|3k
ESPEN practical guideline: Clinical Nutrition in cancer
|Clinical Nutrition|2021|1.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k